Sustained Acoustic Medicine Device sam® Offers an Alternative Solution to Pain Medication and Surgery

JUNE 9, 2020

Sustained acoustic medicine device (sam®) from ZetrOZ Systems offers physicians and orthopedic surgeons an alternative solution to pain medication and surgery for their patients.

Medical providers can prescribe sam®, the only FDA-cleared long-duration ultrasound device, for prescription home-use to treat arthritis and soft tissue injuries.

sam® is a non-invasive prescription medical device that is applied over the target injury and delivers a localized treatment. The device is an excellent option for avoiding medication and delaying surgery, as well as improving postoperative healing and surgical outcomes. sam® is especially beneficial for patients who struggle with poor healing capability.

In addition to accelerating and improving the healing process, sam® is also a very effective treatment for pain arising from conditions such as arthritis, back spasms, disk herniation and tendonitis.

Sixty million people suffer from arthritis and 50 million people struggle with back pain in the United States alone. The leadership team at ZetrOZ Systems set a goal to help 100 million patients who are in pain or facing surgery. sam® does not block or mask pain. The device treats the damaged tissue and inflammatory response that causes it, getting to the root of the problem. ZetrOZ Systems believes that not all patients require surgery or medication.

“We want physicians and orthopedic surgeons to know they are not limited in the options they can offer patients. sam® gives them a viable, convenient alternative to prescribing drugs or putting patients under the knife,” said Dr. George Lewis, chief executive officer of ZetrOZ Systems.

While sam® is technologically sophisticated, it is also easy to use and apply, making it the perfect choice for home application by patients. The solution is convenient, as patients can engage in most activities while wearing it. sam® ships directly to the patient’s home, conserving clinic time and requiring little followup from medical providers.

Medical providers can prescribe sam® using a simple Rx form available at samrecover.com. Patients typically undergo treatment for eight to 10 weeks. Each treatment includes the sam® device and five to eight packs of ultrasound coupling patches. Those with chronic arthritis pain will continue to use the device beyond 10 weeks to maintain their condition.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version